Traders should monitor the outcome of Moderna's appeal to the Federal Circuit, as a negative ruling could trigger a $1.3 billion payment. The settlement removes long-term royalty uncertainty for Moderna's vaccine pipeline but creates near-term cash flow pressure.
MRNA drugs
MRNA drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $53.65entry
- T+1 · 9mo ago −2.18%α −0.87% · $52.48
- T+5 · 8mo ago −0.84%α +1.40% · $53.20
- T+20 · 8mo ago −8.52%α −4.73% · $49.08
- T+60 · 6mo ago −14.15%α −25.45% · $46.06
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all ongoing patent infringement litigation related to its vaccines, including Spikevax and mRESVIA. Moderna will make a $950 million noncontingent payment by July 8, 2026, and may face an additional $1.3 billion contingent payment depending on the outcome of its appeal regarding U.S. government contract protections under 28 U.S.C. 1498.
Key Financial Metrics
Key Facts
- Moderna agreed to pay $950 million noncontingent lump sum to Arbutus/Genevant by July 8, 2026.
- An additional contingent payment of up to $1.3 billion may be required if Moderna loses its appeal on 28 U.S.C. 1498 defense.
- The settlement resolves all worldwide litigation related to Spikevax, mRESVIA, and provides certainty for Moderna's infectious disease portfolio with no future royalties.
- If the Federal Circuit rules that 1498 bars infringement claims for some vaccine doses, the contingent payment will be prorated.
- Arbutus/Genevant must return the contingent payment plus interest if a final decision later favors Moderna.
Financial Impact
Immediate cash outflow of $950 million and potential additional liability of up to $1.3 billion, representing approximately 5.7% of Moderna's $22.8B market cap if fully paid.
Risk Factors
- Contingent $1.3 billion payment obligation if Moderna loses its 1498 appeal
- Potential cash flow strain from large near-term payment
- Market perception of admitting infringement liability despite appeal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000047 |
| Document: 0001682852-26-000047-index-headers.html | 0001682852-26-000047 |
| Document: 0001682852-26-000047-index.html | 0001682852-26-000047 |
| Document: 0001682852-26-000047.txt | 0001682852-26-000047 |
Track record
26 reports on MRNA
5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.10% at T+5 after the Aug 31, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
- Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
- Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
- Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
- Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
- Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
- Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
- Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers